Long-term adipocytokine changes after Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: A comparative minireview

Figure 1 Evidence-informed pathways linking metabolic-bariatric surgery to adipokine remodeling and metabolic risk markers. Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) reduce adipose-tissue mass and inflammation and alter gut-hormone, bile-acid, and microbiota signaling. These changes are associated with lower leptin, resistin, and chemerin and higher adiponectin, together with improved insulin sensitivity and inflammatory risk markers. Direct comparative evidence suggests broadly similar leptin and chemerin changes after RYGB and LSG, whereas adiponectin findings are mixed across small studies. RYGB: Roux-en-Y gastric bypass; LSG: Laparoscopic sleeve gastrectomy.